drugset / Trial / NCT00079716
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and activity of SGN-40 in a weekly dosage schedule as a single agent.
Timeline
- Start
- 2004-03
- Primary completion
- 2007-08
- Completion
- 2007-11
Publications
- Results Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May;121(4):592-6. doi: 10.1046/j.1365-2141.2003.04322.x.
- Results Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010 May;95(5):845-8. doi: 10.3324/haematol.2009.008003. Epub 2010 Feb 4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dacetuzumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | dacetuzumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | dacetuzumab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Subject | dacetuzumab | Monoclonal antibody | 16 mg/kg | Intravenous |